The inhibitory regulators, known as immune checkpoints, prevent overreaction of the
immune system, avoid normal tissue damage, and maintain immune homeostasis during the …

Biomarkers are vital in healthcare as they provide valuable insights into disease diagnosis,
prognosis, treatment response, and personalized medicine. They serve as objective …

Immune checkpoint inhibitors are monoclonal antibodies (mAbs) directed against negative
immunologic regulators that are used to restore the immune response against cancer …

Introduction Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, and
relatively chemoresistant and radioresistant malignancy with limited therapeutic options. Our …

Monoclonal antibodies have been approved by the Food and Drug Administration for the
treatment of various human cancers. More recently, oligonucleotide aptamers have risen …

Leishmaniasis is a neglected disease, for which current treatment presents numerous
issues. Leishmania amazonensis is the etiological agent of cutaneous and diffuse …

Immune checkpoints are emerging as novel targets for cancer therapy, and antibodies
against them have shown remarkable clinical efficacy with potential for combination …

Background Bladder cancer (BC) is one of the most common malignancies of the urinary
tract. The role of transient receptor potential melastatin 7 (TRPM7) in BC remains unclear …

Breast cancer, the most common cancer in women worldwide, is curable in∼ 70–80% of
patients with early-stage, non-metastatic disorder. However, advanced breast cancer with …

Neutrophils play an important role in the outcome of leishmaniasis, contributing either to
exacerbating or controlling the progression of infection, a dual effect whose underlying …